Venetoclax and Azacitidine in Patients With AML With Poor-Risk Cytogenetics With or Without TP53 Mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Outcomes in Patients With Poor-risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine
Clin. Cancer Res 2022 Aug 25;[EPub Ahead of Print], DA Pollyea, KW Pratz, AH Wei, V Pullarkat, BA Jonas, C Recher, S Babu, AC Schuh, M Dail, Y Sun, J Potluri, B Chyla, CD DiNardoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.